Distinguished in Temporal Arteritis

Dr. Byron L. Lam

Ophthalmology
University Of Miami
900 Nw 17th St, 
Miami, FL 
Accepting New Patients
Offers Telehealth
Distinguished in Temporal Arteritis
University Of Miami
900 Nw 17th St, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Byron Lam is an Ophthalmologist in Miami, Florida. Dr. Lam is rated as a Distinguished provider by MediFind in the treatment of Temporal Arteritis. His top areas of expertise are X-Linked Retinitis Pigmentosa (XLRP), Retinitis Pigmentosa, Optic Nerve Atrophy, Vitrectomy, and Nerve Decompression. Dr. Lam is currently accepting new patients.

His clinical research consists of co-authoring 202 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Temporal Arteritis.

Specialties
Ophthalmology
Licenses
Ophthalmology in FL
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

UNIVERSITY OF MIAMI
900 Nw 17th St, Miami, FL 33136
Other Locations
UNIVERSITY OF MIAMI
1611 Nw 12 Th Ave, Jackson Memorial Hospital, Miami, FL 33136
UNIVERSITY OF MIAMI
1601 Nw 12th Ave, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA
An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: Injection of scAAV2-P1ND4v2
Study Phase: Phase 1
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Enrollment Status: Enrolling_by_invitation
Publish Date: April 27, 2025
Intervention Type: Drug
Study Drug: ALK-001
Study Phase: Phase 2
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Enrollment Status: Terminated
Publish Date: July 12, 2024
Intervention Type: Drug, Other
Study Drug: Ultevursen
Study Phase: Phase 2/Phase 3
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: AGTC-402
Study Phase: Phase 1/Phase 2
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: rAAV2tYF-PR1.7-hCNGB3
Study Phase: Phase 1/Phase 2
Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss
Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss
Enrollment Status: Terminated
Publish Date: June 16, 2022
Intervention Type: Drug, Procedure
Study Phase: Phase 3
Natural History Study of CEP290-Related Retinal Degeneration
Natural History Study of CEP290-Related Retinal Degeneration
Enrollment Status: Completed
Publish Date: May 19, 2022
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2022
Intervention Type: Drug, Other
Study Drug: QR-1123
Study Phase: Phase 1/Phase 2
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System
New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System
Enrollment Status: Terminated
Publish Date: December 23, 2021
Biomechanics of Optic Neuropathy
Biomechanics of Optic Neuropathy
Enrollment Status: Terminated
Publish Date: October 23, 2020
Intervention Type: Device
A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION
A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION
Enrollment Status: Terminated
Publish Date: October 12, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Enrollment Status: Terminated
Publish Date: July 20, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
Clinical and Genetic Characterization of Individuals With Achromatopsia
Clinical and Genetic Characterization of Individuals With Achromatopsia
Enrollment Status: Completed
Publish Date: October 13, 2017
View 14 Less Clinical Trials

201 Total Publications

Characterizing Retinal Mitochondrial Function and Its Relations to Intraretinal Thicknesses in Healthy Adults.
Characterizing Retinal Mitochondrial Function and Its Relations to Intraretinal Thicknesses in Healthy Adults.
Journal: Current eye research
Published: July 09, 2025
Similar Doctors
Distinguished in Temporal Arteritis
Dr. Michael A. Schaffer
Ophthalmology
Distinguished in Temporal Arteritis
Dr. Michael A. Schaffer
Ophthalmology

Delray Eye Associates PA

16201 S Military Trl, 
Delray Beach, FL 
 (45.0 miles away)
561-498-8100
Languages Spoken:
English
See accepted insurances

Michael Schaffer is an Ophthalmologist in Delray Beach, Florida. Dr. Schaffer is rated as a Distinguished provider by MediFind in the treatment of Temporal Arteritis. His top areas of expertise are Strabismus, Optic Nerve Atrophy, Optic Atrophy Type 1, and Temporal Arteritis.

Advanced in Temporal Arteritis
Dr. Joshua Pasol
Ophthalmology | Neurology
Advanced in Temporal Arteritis
Dr. Joshua Pasol
Ophthalmology | Neurology

University Of Miami

1611 Nw 12 Th Ave, Jackson Memorial Hospital, 
Miami, FL 
 (0.1 miles away)
305-355-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Pasol is an Ophthalmologist and a Neurologist in Miami, Florida. Dr. Pasol is rated as a Distinguished provider by MediFind in the treatment of Temporal Arteritis. His top areas of expertise are Optic Neuritis, Papilledema, Pseudotumor Cerebri Syndrome, Vitrectomy, and Stent Placement.

Advanced in Temporal Arteritis
Dr. Jeffrey M. Perlman
Ophthalmology
Advanced in Temporal Arteritis
Dr. Jeffrey M. Perlman
Ophthalmology

Eye Associates Of Boca Raton, P.A.

950 Nw 13th St, 
Boca Raton, FL 
 (39.9 miles away)
561-391-8300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jeffrey Perlman is an Ophthalmologist in Boca Raton, Florida. Dr. Perlman is rated as a Distinguished provider by MediFind in the treatment of Temporal Arteritis. His top areas of expertise are Oculomotor Apraxia Cogan Type, Blepharitis, Tolosa Hunt Syndrome, and Temporal Arteritis. Dr. Perlman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lam's expertise for a condition
ConditionClose
View All 17 Distinguished Conditions
View All 11 Advanced Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile